Latest Pharma Insights
US FDA Proposing White House-Aligned Policies For User Fee Agreements
User fee program changes traditionally are technical and FDA-specific, but the Trump Administration appears to also want policies advocating its “America First” agenda included.
HBW Insight - February 18, 2026
User fee program changes traditionally are technical and FDA-specific, but the Trump Administration appears to also want policies advocating its “America First” agenda included.
HBW Insight - February 18, 2026
Senate HELP Committee Recommends Tightening Food Safety Oversight Without Cutting Self-GRAS
GRAS observations included a report on modernizing FDA published as consumer health industry and food safety advocacy and research groups meet with FDA and OMB officials to offer recommendations for and against a proposed rule agency intends to publish on eliminating self-affirmed GRAS option.
HBW Insight - February 18, 2026
GRAS observations included a report on modernizing FDA published as consumer health industry and food safety advocacy and research groups meet with FDA and OMB officials to offer recommendations for and against a proposed rule agency intends to publish on eliminating self-affirmed GRAS option.
HBW Insight - February 18, 2026
Chinese ADC, Cell/Gene Therapy Biotechs Ride Funding Spree
2026 has already seen several major new funding rounds for Chinese biopharma ventures, including a $70m financing for CAR-T specialist Oricell and a $40m Angel round for ADC specialist Tosun.
Scrip - February 18, 2026
2026 has already seen several major new funding rounds for Chinese biopharma ventures, including a $70m financing for CAR-T specialist Oricell and a $40m Angel round for ADC specialist Tosun.
Scrip - February 18, 2026
Chinese ADC, Cell/Gene Therapy Biotechs Ride Funding Spree
2026 has already seen several major new funding rounds for Chinese biopharma ventures, including a $70m financing for CAR-T specialist Oricell and a $40m Angel round for ADC specialist Tosun.
Scrip - February 18, 2026
2026 has already seen several major new funding rounds for Chinese biopharma ventures, including a $70m financing for CAR-T specialist Oricell and a $40m Angel round for ADC specialist Tosun.
Scrip - February 18, 2026
FDA Early Alert Links Injuries, Death To Trividia Blood Glucose Devices
The US FDA says incorrect code messages from some Trividia glucose measurement devices could result in delayed treatment and serious patient harm.
Medtech Insight - February 17, 2026
The US FDA says incorrect code messages from some Trividia glucose measurement devices could result in delayed treatment and serious patient harm.
Medtech Insight - February 17, 2026
Tariff Impact Weighs on Terumo Despite Strong North America Growth And OrganOx Gains
Terumo reported record-high revenue for the third quarter, driven by strong demand in North America, where revenue increased 9% excluding foreign exchange impact.
Medtech Insight - February 17, 2026
Terumo reported record-high revenue for the third quarter, driven by strong demand in North America, where revenue increased 9% excluding foreign exchange impact.
Medtech Insight - February 17, 2026
Medline Recalls Beds After Reports Of Injuries and Deaths Due To Fire, Entrapment
Medline Industries has recalled several adjustable hospital bed models due to electrical hazards in the wiring that may result in the beds catching fire. The company also received reports of patients being trapped in the beds.
Medtech Insight - February 17, 2026
Medline Industries has recalled several adjustable hospital bed models due to electrical hazards in the wiring that may result in the beds catching fire. The company also received reports of patients being trapped in the beds.
Medtech Insight - February 17, 2026
BREAKING: Danaher Pledges To Acquire Masimo For $9.9bn, Expanding Patient Monitoring Footprint
Under the terms of the agreement, Danaher will acquire all outstanding Masimo shares for $180 per share in cash. The company plans to finance the deal through a combination of cash on hand and proceeds from debt financing.
Medtech Insight - February 17, 2026
Under the terms of the agreement, Danaher will acquire all outstanding Masimo shares for $180 per share in cash. The company plans to finance the deal through a combination of cash on hand and proceeds from debt financing.
Medtech Insight - February 17, 2026
US FDA Proposing White House-Aligned Policies For User Fee Agreements
User fee program changes traditionally are technical and FDA-specific, but the Trump Administration appears to also want policies advocating its “America First” agenda included.
HBW Insight - February 18, 2026
User fee program changes traditionally are technical and FDA-specific, but the Trump Administration appears to also want policies advocating its “America First” agenda included.
HBW Insight - February 18, 2026
Senate HELP Committee Recommends Tightening Food Safety Oversight Without Cutting Self-GRAS
GRAS observations included a report on modernizing FDA published as consumer health industry and food safety advocacy and research groups meet with FDA and OMB officials to offer recommendations for and against a proposed rule agency intends to publish on eliminating self-affirmed GRAS option.
HBW Insight - February 18, 2026
GRAS observations included a report on modernizing FDA published as consumer health industry and food safety advocacy and research groups meet with FDA and OMB officials to offer recommendations for and against a proposed rule agency intends to publish on eliminating self-affirmed GRAS option.
HBW Insight - February 18, 2026
January Brings A Slew Of Price Spikes For UK Generics
The UK generics market kicked off the new year with huge triple-digit average price rises for a host of products. Market researcher WaveData reveals the details.
Generics Bulletin - February 17, 2026
The UK generics market kicked off the new year with huge triple-digit average price rises for a host of products. Market researcher WaveData reveals the details.
Generics Bulletin - February 17, 2026
Gotenfia Approval Sets Stage For Multi-Player Competition On EU Golimumab
European Commission authorization clears the way for regional launches, as the newly opened golimumab biosimilars segment begins to take shape.
Generics Bulletin - February 17, 2026
European Commission authorization clears the way for regional launches, as the newly opened golimumab biosimilars segment begins to take shape.
Generics Bulletin - February 17, 2026
‘It’s Time For The Biosimilar Program To Evolve’ – Biosimilars Forum’s Reed Sees Need For Change
As the US biosimilars market sees long-desired changes in areas such as regulatory streamlining and interchangeability, Julie Reed – executive director of the Biosimilars Forum – says there are still aspects that need to evolve.
Generics Bulletin - February 17, 2026
As the US biosimilars market sees long-desired changes in areas such as regulatory streamlining and interchangeability, Julie Reed – executive director of the Biosimilars Forum – says there are still aspects that need to evolve.
Generics Bulletin - February 17, 2026
Podcast: Hansa Biopharma On Clearing The Path To Kidney Transplant
Renée Aguiar-Lucander, CEO of Hansa Biopharma, discussed the company’s leading asset, its journey toward US FDA approval and the trials and tribulations of completing a Phase III program.
In Vivo - February 17, 2026
Renée Aguiar-Lucander, CEO of Hansa Biopharma, discussed the company’s leading asset, its journey toward US FDA approval and the trials and tribulations of completing a Phase III program.
In Vivo - February 17, 2026